JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Severity of liver disease among chronic hepatitis C patients: an observational study of 4594 patients in 5 EU countries.
J. Gastroenterol. Hepatol.
PUBLISHED: 07-04-2014
Show Abstract
Hide Abstract
Assessment of the severity of liver disease following infection with hepatitis C virus (HCV) is important in treatment selection and prognosis. As invasive liver biopsy procedures are regarded as the reference method to assess the stage of fibrosis, it is important to identify patient characteristics that are predictive of liver fibrosis severity. The aim of the study was to describe the distribution of liver severity scores, clinical characteristics, and physicians' assessment of fibrosis among HCV patients in 5 European countries.
Related JoVE Video
Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
Pharmacoepidemiol Drug Saf
PUBLISHED: 01-14-2014
Show Abstract
Hide Abstract
We sought to determine the incidence and risks for severe thrombocytopenia (platelets?
Related JoVE Video
Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.
Curr Med Res Opin
PUBLISHED: 12-20-2011
Show Abstract
Hide Abstract
To evaluate the World Health Organizations (WHO) Bleeding Scale in two studies of eltrombopag in adults with chronic immune thrombocytopenia (ITP).
Related JoVE Video
Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients.
J Med Econ
PUBLISHED: 11-04-2011
Show Abstract
Hide Abstract
Thrombocytopenia (TCP), defined as platelet counts <150,000/µL, is a common complication of severe chronic liver disease (CLD). This retrospective study estimated the prevalence of thrombocytopenia in a large population of CLD patients and compared medical resource utilization and medical care costs by TCP status.
Related JoVE Video
Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.
Qual Life Res
PUBLISHED: 04-04-2011
Show Abstract
Hide Abstract
To assess the validity and reliability of the fatigue subscale of the Functional Assessment of Chronic Illness Therapy (FACIT-F), a 6-item subset from the thrombocytopenia subscale of the Functional Assessment of Cancer Therapy (FACT-Th6) and the Short Form-36 Version 2 (SF-36v2) in 2 clinical trials of the thrombopoietin receptor agonist eltrombopag in chronic immune thrombocytopenia (ITP) patients.
Related JoVE Video
Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
J Med Econ
PUBLISHED: 02-25-2011
Show Abstract
Hide Abstract
Thrombocytopenia is a significant risk for patients with chronic HCV infection and a common side-effect of treatment with pegylated (PEG) interferon (IFN). Thrombocytopenia predisposes patients to bleeding and requirements for platelet transfusions, and may thus place an increased burden on patients and on medical resource utilisation.
Related JoVE Video
Patients benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies.
Ann Pharmacother
PUBLISHED: 02-02-2010
Show Abstract
Hide Abstract
Idiopathic thrombocytopenic purpura (ITP) primarily is a disorder of adults characterized by autoantibody-induced platelet destruction and reduced platelet production, leading to a low peripheral blood platelet count. The long-term management of many patients with chronic ITP is unsatisfactory, largely due to the variable efficacy and risks of severe adverse effects associated with current treatment options.
Related JoVE Video
Treatment practices in adults with chronic immune thrombocytopenia - a European perspective.
Eur. J. Haematol.
PUBLISHED: 10-21-2009
Show Abstract
Hide Abstract
Immune thrombocytopenia (ITP) is characterised by platelet destruction and impaired production leading to isolated thrombocytopenia. The aim of this study, comprising a retrospective longitudinal cohort study complemented by a Delphi panel of 35 physicians, was to describe standard treatment practices and treating physicians perception and preferences for available treatment options in chronic ITP. The medical records of 610 patients were reviewed over 12 months. Mean age at the start of the observational period was 54.6 yr, median platelet count 77 x 10(9)/L with 41% of patients having symptoms of ITP. Treated patients (61%) received an average of 2.7 medications either for ITP or ITP treatment-related side effects. An array of products was used, but the most frequent were corticosteroids. Delphi panel physicians (45%) indicated the main goals for treatment were to increase platelet levels to at least 30 x 10(9)/L to prevent bleeding or haemorrhage. The majority (89%) indicated that personal experience influenced treatment choice. Most (>80%) rated splenectomy and high-dose corticosteroids as the most effective but were concerned about side effects, and many (75%) would like access to interventions with improved efficacy and safety. The study highlights the need for updated evidence-based treatment guidelines to assist physicians in patient treatment decisions and to realise improvements in patient outcomes. It also identified perceived shortcomings of existing therapies and the need to establish an evidence base for newer interventions that could potentially make lasting response to treatment with fewer adverse effects an achievable goal.
Related JoVE Video
Analysis of the impact and burden of illness of adult chronic ITP in the US.
Curr Med Res Opin
PUBLISHED: 10-20-2009
Show Abstract
Hide Abstract
Chronic idiopathic thrombocytopenic purpura (ITP), the predominant diagnosis in the ICD-9-CM category of primary thrombocytopenia in adults, is an autoimmune disease characterized by autoantibody-mediated platelet destruction and reduced platelet production. The objective of this study was to describe ITP patient demographics, treatment, medical care resource utilization, and costs from a real-world situation.
Related JoVE Video
A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries.
Value Health
PUBLISHED: 08-20-2009
Show Abstract
Hide Abstract
The production of accurate and culturally relevant translations of patient reported outcome (PRO) measures is essential for the success of international clinical trials. Although there are many reports in publication regarding the translation of PRO measures, the techniques used to produce single translations for use in multiple countries (global translations) are not well documented. This article addresses this apparent lack of documentation and presents the methodology used to create global translations of the Chronic Liver Disease Questionnaire-Hepatitis C Virus (CLDQ-HCV). The challenges of creating a translation for use in multiple countries are discussed, and the criteria for a global translation project explained. Based on a thorough translation and linguistic validation methodology including a concept elaboration, multiple forward translations, two back translations, reviews by in-country clinicians and the instrument developer, pilot testing in each target country and multiple sets of proofreading, the key concept of the global translation methodology is consistent international harmonization, achieved through the involvement of linguists from each target country at every stage of the process. This methodology enabled the successful resolution of the translation issues encountered, and resulted in consistent translations of the CLDQ-HCV that were linguistically and culturally appropriate for all target countries.
Related JoVE Video
Thrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease.
Dig. Dis. Sci.
Show Abstract
Hide Abstract
Thrombocytopenia in chronic liver disease (CLD) typically reflects disease severity and may indicate an increased risk for bleeding.
Related JoVE Video
Patient-reported treatment burden of chronic immune thrombocytopenia therapies.
BMC Blood Disord
Show Abstract
Hide Abstract
Chronic immune thrombocytopenia (ITP) is a debilitating autoimmune disorder that causes a reduction in blood platelets and increased risk of bleeding. ITP is currently managed with various pharmacologic therapies and splenectomy.This study was conducted to assess patient perceived and reported treatment side effects, as well as the perceived burden or bother, and need to reduce or stop treatment, associated with these side effects among adult patients with chronic ITP.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.